imbruvica
Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia
December 7, 2020Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica
Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …
Janssen’s Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia
September 7, 2020Sales and Marketing Europe, Janssen, imbruvica, pharma
The European Commission (EC) has moved to expand the existing approval of Janssen’s Imbruvica (ibrutinib) in chronic lymphocytic leukaemia (CLL) …
AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod
April 22, 2020Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia
AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …
Janssen chalks up two more indications in Europe for Imbruvica combo therapies
August 14, 2019Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma
Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …
Janssen secures two positive CHMP opinions for Imbruvica label expansions
July 1, 2019Sales and Marketing CHMP, EMA, Europe, Janssen, imbruvica, pharma
Janssen’s Imbruvica (ibrutinib) has racked up two positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human …
Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia
January 29, 2019Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma
It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …
NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients
August 10, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …
Janssen debuts promising new cancer data at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma
Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …
Scotland recommends Janssen’s Imbruvica for leukaemia
April 11, 2017Manufacturing and Production, Sales and Marketing SMC, imbruvica, leukaemia
Janssen has been celebrating the news that its Imbruvica (ibrutinib) has been recommended by the Scottish Medicines Consortium (SMC) for …
NICE approves Imbruvica for second-line leukaemia treatment
January 26, 2017Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica
NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …
J&J’s Imbruvica scores fifth FDA lymphoma approval
January 20, 2017Medical Communications, Research and Development, Sales and Marketing FDA, Marginal Zone Lymphoma, imbruvica
Johnson & Johnson’s Imbruvica (ibrutinib) has scored its fifth indication approval in the US for the treatment of Marginal Zone …
Janssen reveals positive results from longest follow-up of Imbruvica
December 7, 2016Research and Development AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica
Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica …
Lowered price wins NICE approval for Janssen leukaemia treatment
November 25, 2016Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica
After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …
NICE knocks back Janssen rare disease drug
October 13, 2016Medical Communications Janssen, NICE, imbruvica
NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …
NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund
August 18, 2016Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica
NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …
Latest content
FibroFind appoints Lee Borthwick as CEO
